New Diabetic Drug Similar to Byetta, Victoza Approved, Despite Cancer Risks
The FDA has approved a new diabetes drug, Trulicity, that may carry similar thyroid and pancreatic cancer risks as existing diabetes treatments.
Tag Archives: Januvia
-
-
Byetta Settlements Reached in 84 Cases, But Hundreds of Lawsuits Remain
AstraZeneca announced it has settled 84 Byetta lawsuits, but still faces more than 400 claims involving allegations that the diabetes drug caused pancreatic cancer, thyroid cancer or pancreatitis.
-
Discovery Moving Forward in Byetta, Januvia Cancer Lawsuits
Following a status conference, deadlines for discovery have been established in the pancreatic cancer lawsuits.
-
Bydureon Side Effects Linked to Injection Site Reactions
Bydureon, a long-acting version of Byetta, has been linked to severe injection site reactions, the FDA warns.
-
Insulin and Metformin for Diabetics May Increase Heart Risks: Study
A new study suggests that taking insulin with metformin increases a diabetic's risk of heart problems and death, and highlights the confusion over diabetes drug choices.
-
Victoza Recall Urged By Public Citizen Over Pancreatitis Risks
Public Citizen is demanding the FDA ban Victoza from the market following a report the group says shows a causal link between the diabetes drug and acute pancreatitis.
-
Januvia, Byetta Pancreatitis Risk Questioned by Researchers
Chinese researchers say they could find no link between incretin mimetic-based diabetes drugs and an increased risk of pancreatitis.
-
Nesina Leads Similar Diabetes Drugs in Adverse Events: Report
A look at diabetes drug adverse event reports suggests Nesina is the most dangerous and finds evidence of pancreatic cancer risks.
-
Diabetes Drug Pancreatic Cancer Risk Questioned by FDA, EMA
The FDA and EMA say they can find no link between certain diabetes drugs and pancreatic cancer, despite other studies to the contrary.
-
Motion to Establish Byetta MDL for Thyroid Cancer Lawsuits Withdrawn
A request that Byetta thyroid cancer lawsuits be included in diabetes drug pancreatic cancer litigation has been suddenly withdrawn.
